SAN FRANCISCO — Cabozantinib induced early tumor shrinkage — associated with prolonged OS — at a higher rate and to a greater degree than everolimus among patients with advanced renal cell carcinoma, according to data from the phase 3 METEOR study presented at Genitourinary Cancers Symposium.

“Early tumor shrinkage is defined as a decrease in the sum of the longest diameters of the target lesion in the first CT scan performed after initiating therapy,” Ignacio Duran, MD, PhD, of the department of medical oncology at Hospital University Virgen del Rocio Instituto de Biomedicina de Sevilla in Spain, said during his presentation. “It is also true that early tumor shrinkage has been correlated with better survival in previous works in metastatic kidney cancer.”